← All companies

XLO

Xilio Therapeutics, Inc.

XLO Nasdaq Pharmaceutical Preparations EDGAR ↗

$9.05

-0.03 -0.33%

Key statistics

from XBRL data in SEC filings

Market cap

$52.3M

Revenue (TTM)

$53.5M

Net income (TTM)

-$31.3M

EPS (TTM)

$-2.28

P/E ratio

—

Dividend yield

—

Free cash flow

-$5.51M

Cash

$150M

Total assets

$163M

Gross margin

—

52-week range

$6.47 – $12.74

Recent SEC filings

40 most recent

Annual, quarterly & current reports

8-K Director or officer change; Shareholder vote results Jun 12, 2026 10-Q Quarter ended 2026-03-31 May 12, 2026 8-K Results of operations (earnings release) May 12, 2026 8-K Director or officer change Apr 16, 2026 10-K Fiscal year ended 2025-12-31 Mar 23, 2026 8-K Results of operations (earnings release) Mar 23, 2026 8-K Modified rights of security holders; Amended charter or bylaws Mar 12, 2026 8-K Regulation FD disclosure Mar 9, 2026 8-K Shareholder vote results Feb 24, 2026 8-K Entered a material agreement; Regulation FD disclosure Feb 12, 2026 8-K Results of operations (earnings release); Director or officer change Jan 8, 2026 8-K Regulation FD disclosure Jan 5, 2026 8-K Director or officer change; Shareholder vote results Nov 25, 2025 10-Q Quarter ended 2025-09-30 Nov 13, 2025 8-K Results of operations (earnings release) Nov 13, 2025 8-K Regulation FD disclosure Nov 7, 2025 8-K Delisting notice or listing-rule failure Oct 3, 2025 8-K Other events Sep 9, 2025 8-K Delisting notice or listing-rule failure Aug 28, 2025 10-Q Quarter ended 2025-06-30 Aug 14, 2025 8-K Results of operations (earnings release) Aug 14, 2025 8-K Shareholder vote results Jun 12, 2025 8-K Director or officer change Jun 10, 2025 8-K Entered a material agreement; Regulation FD disclosure; Other events Jun 3, 2025 8-K Regulation FD disclosure; Other events Jun 2, 2025 10-Q Quarter ended 2025-03-31 May 8, 2025 8-K Results of operations (earnings release) May 8, 2025 8-K Delisting notice or listing-rule failure Apr 8, 2025 8-K Entered a material agreement Mar 11, 2025 10-K Fiscal year ended 2024-12-31 Mar 11, 2025 8-K Results of operations (earnings release) Mar 11, 2025 8-K Entered a material agreement; Unregistered sale of equity; Regulation FD disclosure; Other events Feb 12, 2025 8-K Regulation FD disclosure; Other events Jan 21, 2025 8-K Unregistered sale of equity; Regulation FD disclosure; Other events Dec 19, 2024 10-Q Quarter ended 2024-09-30 Nov 7, 2024 8-K Results of operations (earnings release); Regulation FD disclosure; Other events Nov 7, 2024 8-K Delisting notice or listing-rule failure Sep 13, 2024 10-Q Quarter ended 2024-06-30 Aug 8, 2024 8-K Results of operations (earnings release) Aug 8, 2024 8-K Shareholder vote results Jun 17, 2024